Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01299701
Registration number
NCT01299701
Ethics application status
Date submitted
10/02/2011
Date registered
18/02/2011
Date last updated
14/02/2017
Titles & IDs
Public title
A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors
Query!
Scientific title
An Open-label Single Center Study to Characterize the Absorption, Distribution, Metabolism, and Excretion (ADME) of ASA404 After a Single Intravenous Infusion of 3000 mg [14C]ASA404 in Patients With Advanced Solid Tumor Malignancies
Query!
Secondary ID [1]
0
0
CASA404A2108
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Advanced Solid Tumors
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - ASA404
Experimental: ASA404 -
Treatment: Drugs: ASA404
(5,6-dimethylxanthenone-4-acetic acid) DMXAA or DXAA
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
characterize the pharmacokinetic profiles of ASA404 and any potential metabolite(s) in plasma and pharmacokinetic profiles of the total radioactivity in blood and plasma after a single intravenous infusion of 3000 mg [14C] ASA404 (60 µCi)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
12 months
Query!
Secondary outcome [1]
0
0
determine the rate and routes of excretion of ASA404 (60 µCi)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
12 months
Query!
Secondary outcome [2]
0
0
identify metabolite(s) structures(s) and quantify the metabolites of ASA404 in plasma, urine, and feces in order to elucidate the biotransformation pathways and determine the essential clearance mechanisms of ASA404
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
12 months
Query!
Secondary outcome [3]
0
0
collect safety data (including electrocardiograms) for ASA404
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
12 months
Query!
Eligibility
Key inclusion criteria
- Histologically proven diagnosis of advanced or metastatic solid tumors for whom either
refractory to standard therapy exists, or for whom treatment with an investigational
agent alone or in combination with docetaxel, paclitaxel, carboplatin, or paclitaxel
plus carboplatin is appropriate;
- ANC= 1.5 x 109/L;
- Hgb = 9.0 g/L;
- PLT = 100,000/mm3;
- Total bilirubin = 1.5;
- Willing and able to remain in the clinic for at least 4 days
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Patients with CNS and/or leptomeningeal disease metastases allowed on the study unless
asymptomatic and not requiring corticosteroid therapy. Patients having any clinical
signs of CNS metastases must have a CT or MRI of the brain performed to rule out CNS
metastases in order to be eligible for study participation. Patients who have had
brain metastases surgically removed or irradiated with no residual disease confirmed
by imaging are allowed;
- Patients unable to undergo intravenous infusion;
- Patients with a Baseline 12-lead EGC QTc of >450 msec;
- Radiotherapy in less than two (2) weeks prior to study entry;
- A history of noncompliance to medical regimens or inability or unwillingness to return
for all scheduled visits
Other protocol-defined inclusion/exclusion criteria may apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/07/2009
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
7
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
New Zealand
Query!
State/province [1]
0
0
Grafton, Auckland
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is designed to characterize the absorption, distribution, metabolism and excretion
(ADME) of ASA404 following a single intravenous administration of 3000 mg (approximately 1800
mg/m2) ASA404 containing 60 µCi of 14C over a period of 20 minutes in patients with advanced
solid tumors. Metabolic pathways, route (s) of elimination, distribution characteristics in
plasma and blood, and exposure characterization in plasma and blood, and exposure
characterization of the parent drug and metabolites will be obtained from the study.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01299701
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01299701
Download to PDF